Healthcare Finance >>>

    Payers Should Not Restrict Total Knee Replacement Surgery, Study Finds Cost Effective

    by Elizabeth Krutoholow Total knee replacement surgery is a cost-effective treatment and should not be restricted for appropriate patients by payers looking to save money as demand for the procedure increases, said Dr. Joshua Jacobs, president of the American Academy of Orthopaedic Surgeons. This rise in demand is driven by the fact that total knee [...]

    Arena, Vivus’ Obesity Drugs See Continual Uptake, Persistence Key Among Primary Care Docs

    by Elizabeth Krutoholow   Arena’s Belviq and Vivus’ Qsymia have been readily adopted by weight loss experts, according to Dr. Ken Fujioka, director, Nutrition and Metabolic Research and of the Center for Weight Management at Scripps Clinic.   Persistence of use, particularly among primary care doctors will be critical for the companies to maintain this [...]

    Biogen’s Tecfidera Launch Unlikely to Be Hampered By Generic Substitution

    by Elizabeth Krutoholow   Biogen’s Tecfidera is unlikely to face competition from generic dimethyl fumarate, according to physicians interviewed. The company introduced its oral multiple sclerosis (MS) drug in the U.S. in the second quarter this year. In its recent earnings call, Biogen said the launch is “going very well.”   Read More >>>

    House More Flexible in Track and Trace Bill

    Bipartisan legislation in both chambers of Congress would strengthen the pharmaceutical supply chain by creating a single nationwide system of tracking prescription drugs from manufacturer to end user. A key question has thus far prevented enactment of a national supply chain standard: Should the specificity of such a tracking program be unit-level or lot-level? To read more, click here.

    Large Pharma Shifts Focus to Early Stage Licensing Deals

    by Sam Fazeli, Bloomberg Industries   Early-stage drugs were favored in the second quarter. Large pharmaceutical companies have shifted their attention toward discovering and developing drugs at earlier stages in the development cycle.   Only three deals for Phase III assets (5 percent of the total) were inked in the quarter, compared with six (10 [...]

    China Drug Price Cuts Offset by Volume Growth

    by Sam Fazeli, Bloomberg Industries Europe Price cuts that were enforced earlier this year in China have been offset by volume growth, minimizing the challenge for pharmaceutical companies. A 15 percent average price cut was instituted across the essential drug list on February 1, with larger reductions for some more expensive drugs up to 20 [...]

    Biomet IPO May Be Largest for Medical Device Sector in 20 Years

    by Jason McGorman & Michael Manns, Medical Equipment/Devices Team, Bloomberg Industries   A possible initial public offering for Biomet, an orthopedic device company taken private in a 2007 leveraged buyout, may be the largest for the medical device sector in the past 20 years, according to a Bloomberg Industries analysis.   Read more >>>>

    Arena’s Belviq Launch Outpaces Vivus’s Qsymia

    by Andrew Berens, MD and Thomas Smith, Bloomberg Industries Prescriptions of Arena/Eisai’s Belviq for obesity appear strong compared to competitor Vivus’ Qsymia. Prescriptions of Belviq rose 83 percent to 2,162 in its second full week on the market, according to data from Symphony Health. Qsymia did not reach this level until its fifth full week. [...]

    Johnson & Johnson’s Launch of Invokana Bodes Well for SGLT-2 Class

    Compiled by Sam Fazeli, Bloomberg Industries and Elizabeth Krutoholow Johnson & Johnson’s newly launched diabetes drug Invokana appears to have fairly strong uptake, according to data from inThought Research. This may bode well for other agents in the new SGLT-2 class, said Christopher Martin, Senior Principal, Symphony Health Solutions in a webcast with Bloomberg Industries’ [...]

    Lack of RDP Unlikely Threat to Biogen’s Tecfidera EU Patents

    By Asthika Goonewardene, Bloomberg Industries, and Aude Gerspacher, Bloomberg Law   The EU regulatory body’s denial of regulatory data protection (RDP) does not impact the strength of Biogen’s European patents, Aude Gerspacher, a Bloomberg Law writer and editor with more than 10 years’ experience as a patent attorney said in a call with Bloomberg Industries’ [...]

Bloomberg BRIEF Newsletters